©2022 Stanford Medicine
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
Recruiting
I'm InterestedTrial ID: NCT01165762
Purpose
The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone
marrow Transplantation are enrolling patients into a research study to determine if donor
stem cells given after a living related one Haplotype match kidney transplantation will
change the immune system such that immunosuppressive drugs can be completely withdrawn.
Official Title
Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion in HLA Haplotype Match Living Donor Kidney Transplantation
Stanford Investigator(s)
Stephan Busque
Professor of Surgery (Abdominal Transplantation)
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Marc L. Melcher
Professor of Surgery (Abdominal Transplantation)
Richard Hoppe
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)
Eligibility
Inclusion Criteria:
1. All consenting adults who are 18 to 60 years, living donor transplant candidates and
have a haplotype related living donor or > 2 HLA antigen matched, unrelated, living
donor (including at least one HLA-DR antigen match plus at least one antigen match of
either HLA-A or HLA-B).
2. Patients who agree to participate in the study and sign an Informed Consent.
3. Patients who have no known contraindication to administration of rabbit ATG or
radiation.
4. Males and females of reproductive potential who agree to practice a reliable form of
contraception for at least 24 months post-transplant.
5. ABO compatible.
Exclusion Criteria:
1. Previous treatment with rabbit ATG or a known allergy to rabbit proteins.
2. History of malignancy with the exception of non-melanoma skin malignancies.
3. Pregnant women or nursing mothers.
4. Serological evidence of HIV, Hepatitis B or Hepatitis C infection.
5. Seronegative for Epstein-Barr virus, if donor is seropositive.
6. Leukopenia (with a white blood cell count < 3000/mm3) or thrombocytopenia (with a
platelet count < 100,000/mm3).
7. Panel Reactive Antibody greater than 80% or demonstration of donor specific antibody
(DSA).
8. Prior organ transplantation.
9. High risk of primary kidney disease recurrence (e.g atypical HUS). However, patients
with primary FSGS will not be excluded.
Intervention(s):
drug: Immune Tolerance
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Asha Shori, CCRP
650-736-0245